SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES, Revenue Recognition, Cumulative Effect (Details) - USD ($)		Jun. 30, 2018		Dec. 31, 2017
Balance Sheets [Abstract]
Contract assets		$ 7,100,000
Accounts receivable		12,893,893	[1]	$ 4,655,105
Deferred revenue		0		6,400,000
Deferred royalty buy-down		(1,100,000)		(2,500,000)
Deferred tax assets, net		321,603	[1]	1,739,706
Income tax payable		801,800	[1]	68,733
Retained earnings adjustment		60,402,721	[1]	41,939,115
Endo [Member]
Balance Sheets [Abstract]
Accounts receivable		12,893,893		4,655,105
Deferred revenue				(6,400,000)
Deferred royalty buy-down				(2,500,000)
Accounts payable and accrued expenses -third party royalties				(400,000)
Deferred tax assets, net				1,739,706
Income tax payable				0
Retained earnings adjustment				(2,900,000)
ASU 2014-09 [Member] | Endo [Member]
Balance Sheets [Abstract]
Accounts receivable				12,300,000
Deferred revenue				(100,000)
Deferred royalty buy-down				(2,900,000)
Accounts payable and accrued expenses -third party royalties				(900,000)
Deferred tax assets, net				400,000
Income tax payable				(1,400,000)
Retained earnings adjustment				7,400,000
Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member]
Balance Sheets [Abstract]
Accounts receivable		7,100,000
Deferred tax assets, net		(1,200,000)
Income tax payable		(1,300,000)
Retained earnings adjustment		$ 9,700,000
Adjustments / Effect of Change Higher / (Lower) [Member] | ASU 2014-09 [Member] | Endo [Member]
Balance Sheets [Abstract]
Accounts receivable	[2]			7,600,000
Deferred revenue	[3]			6,300,000
Deferred royalty buy-down	[4]			(400,000)
Accounts payable and accrued expenses -third party royalties	[4]			(500,000)
Deferred tax assets, net	[5]			(1,300,000)
Income tax payable	[6]			(1,400,000)
Retained earnings adjustment				$ 10,300,000

[1] As of January 1, 2018, the Company adopted the requirements of ASC 606 using the modified retrospective adoption method, and as a result, there is a lack of comparability of certain amounts to the prior periods presented. See Note 2 for additional discussion.

[2] This adjustment represents the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.

[3] Represents the remaining deferred revenue balance of the prepaid mark-up on cost of goods sold based on sales by non-affiliated sublicensees of Endo outside of the U.S.

[4] Represents the amortization of the royalty buy-down and third party royalties expense associated royalty revenues based on XIALFLEX net sales reported to us by Endo for the fourth quarter of 2017.

[5] To reverse a deferred tax asset associated with the deferred revenue balance of the prepaid mark-up on cost of goods sold by non-affiliated sublicensees of Endo outside of the U.S.

[6] To create a tax liability associated the elimination of the one quarter lag by recognizing royalty revenues based on of XIALFLEX net sales and mark-up on cost of goods sold revenues reported to us by Endo for the fourth quarter of 2017.